Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

ties from MedImmune are not included subsequent to the first quarter of 2009 due to ongoing legal activities as discussed above. Revenue growth expectations are primarily driven by increases in product sales of Avastin, Herceptin, Lucentis and Tysabri.

PDL continues to expect its general and administrative expenses for 2009 to range from $12 million to $15 million, of which approximately 50 percent may be related to legal expense, patent defense and other professional fees. Net income after taxes for 2009 continues to be projected in the range of $185 to $200 million and cash generated in 2009 still is expected to be in the range of $260 to $280 million.

Conference Call Details

To access the live conference call today, May 7, 2009 at 4:30 p.m. Eastern Time via phone, please dial (877) 361-8830 from the United States and Canada or (706) 679-8297 internationally. The conference ID is 97783926. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through May 14, 2009, and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 97783926.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site at http://www.pdl.com and click "Investors." Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL BioPharma, Inc. pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and autoimmune diseases. PDL is focused on maximizing the value of our antibody humanization patents and related assets. PDL receives royalties on sales
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... $5.8 million and provides a good start to Q4.  The orders ... and one in the Middle East ... levels," said Peter Bruijns , President & CEO. "Total bidding ... than they have been for any complete year since the company ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Md., May 20 Martek Biosciences Corporation (Nasdaq: ... of its second quarter of fiscal 2009 on June 3, ... the release, at 4:45 p.m. ET Martek will conduct a ... interested parties may listen to the call live via webcast ...
... Launch into High Growth Brazilian Market for Aesthetic ... announced today the receipt of ANVISA clearance to ... in Brazil. ANVISA (Agencia Nacional de Vigilancia ... regulatory agency charged with clearing all applications to ...
... Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to ... year and guidance on its projected financial performance for the ... , In Q1 2009, ... $0.68 million), representing a 127 percent increase year-over-year from the ...
Cached Biology Technology:Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3
(Date:10/18/2014)... of 2,000 patients referred for evaluation of suspected ... diagnosis for 25 percent, including detection of a ... contributing to disease, according to a study appearing ... released to coincide with the American Society of ... the exons or coding regions of thousands of ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... CHAMPAIGN, Ill. Up to 4 percent of the methane ... have been unable to identify the source of this potent ... culprit: a bit of "weird chemistry" practiced by the most ... the journal Science . The researchers who made ...
... blanket of snow in the winter can help boost ... is one way to ensure that blanket coverage, according ... Agricultural Research Service (ARS) soil scientist David Huggins conducted ... accumulation and soil water levels across entire fields. ARS ...
... NY) Researchers at Albert Einstein College of Medicine ... mechanism that the immune system uses to respond to infection. ... lead to new strategies for boosting effectiveness of all vaccines. ... journal Immunity . Grgoire Lauvau, Ph.D.One way the ...
Cached Biology News:Study identifies prime source of ocean methane 2Study identifies prime source of ocean methane 3No-till farming helps capture snow and soil water 2Early activation of immune response could lead to better vaccines 2
... designed for use with HRP conjugated rabbit polyclonal ... monoclonal coating antibody. • ... non-specific binding between the coating and detection antibodies. ... be used to stabilize newly conjugated antibodies, to ...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
Request Info...
supplied with 10x reaction buffer...
Biology Products: